drugset / Trial / NCT02300363
DDI Study With Multiple-dose LX4211 and Single Dose Rosuvastatin
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study will be conducted as a single-center, open-label, 2-period, single-sequence, drug-drug interaction study to assess the effects of multiple-dose LX4211 400 mg (2 × 200-mg tablets qd × 7 days) on the PK of single-dose rosuvastatin (1 × 10-mg tablet) in healthy male and female subjects.
Timeline
- Start
- 2014-10
- Primary completion
- 2014-11
- Completion
- 2014-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rosuvastatin | Small molecule | 10 mg | Oral |
| Subject | Sotagliflozin | Small molecule | 400 mg | Oral |
Indications
No indication recorded.